EGFR and non-small cell lung carcinoma: For example, the RELAY trial has demonstrated that a dual blockade of the EGFR and VEGF pathways (i.e., ramucirumab plus erlotinib) in EGFR-mutated untreated metastatic NSCLC patients provided superior progression-free survival compared to blocking the EGFR pathway only (placebo plus erlotinib) (6).